Randomized trial might expand use from refractory cases ...
By Bhanvi Satija LONDON, May 18 (Reuters) - French drugmaker Sanofi said on Monday a trial showed its rare disease therapy ...
Phase 3b ENCORE data assess inhaled amikacin in MAC lung disease. Read more on efficacy, safety, and patient-reported ...
And randomized trial shows safety is on par ...
The Rare Lung Disease Program’s mission is to provide state of the art collaborative evaluation and treatment for patients with rare lung diseases. This program exists to better understand rare lung ...
In an interview with The American Journal of Managed Care ® (AJMC ®) at the American Thoracic Society International ...
Researchers report progress in looking for signs of lung cancer in the blood.